XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its third quarter financial results on November 7, 2013 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results, general business updates and a review of additional clinical data and program developments for XP23829, XenoPort’s novel fumaric acid ester product candidate.
To access the conference call via the Internet, go to
. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 77314561.
A replay of the conference call will be available for one week following the event and may be accessed after 8:00 p.m. Eastern Time that same day via the Internet, at
, or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 77314561.
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT
(gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for relapsing-remitting multiple sclerosis and/or psoriasis. REGNITE
(gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort's pipeline of product candidates includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson's disease. To learn more about XenoPort, please visit the Website at
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.